Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study." / Picardi, Marco; Giordano, Claudia. - In: HAEMATOLOGICA. - ISSN 1592-8721. - 106:4(2021), pp. 1226-1227. [10.3324/haematol.2020.278203]

Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."

Picardi, Marco;Giordano, Claudia
2021

2021
Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study." / Picardi, Marco; Giordano, Claudia. - In: HAEMATOLOGICA. - ISSN 1592-8721. - 106:4(2021), pp. 1226-1227. [10.3324/haematol.2020.278203]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/983624
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact